Denver, Colorado (PRWEB) November 27, 2013
Mirada Medical announced that the company has installed its advanced XD3 image analysis software at the prestigious National Institutes of Health (NIH) in Bethesda, Maryland. XD3 will initially be employed for multi-modality image fusion research including PET/CT and PET/MR. The software uniquely affords the ability to compare and quantify multiple modalities and unlimited time points of data.
PET/MR is gaining rapid adoption as a reliable modality for diagnosis and treatment management of a variety of oncologic conditions and Mirada Medical has responded with the industry’s first full-featured PET/MR reading software. PET/MR demonstrates exquisite soft-tissue differentiation for improved localization in areas such as the abdomen and pelvis and more discriminative tissue characterization through functional MR. Mirada’s XD3 software is based on Deformable Image Registration (DIR) which corrects for non-rigid motion. Unlike conventional rigid registration, deformable registration can also correct for differences in patient positioning, thus allowing the fusion of PET/CT and MR scans acquired using standard protocols on different equipment, at different times. XD3 supports the loading of multiple PET/MR studies and swapping of MR sequences in real-time even in a fused view.
“We are proud to have been selected by the National Institutes of Health,” stated Hugh Bettesworth, CEO of Mirada Medical. “The technology defining features of our XD3 software with deformable image registration will support NIH clinicians and researchers in optimizing the clinical benefits of PET/MR while empowering ground breaking research into novel fused image analysis. I firmly believe that novel image analysis and quantification of PET/MR has the potential to redefine the future standard of care,” added Bettesworth.
Mirada Medical will be demonstrating the latest developments for software PET/MR along with its entire suite of solutions for fusion and quantitative reading at the annual Radiological Society of North America meeting (booth 6520, North Hall) December 1 – 5th in Chicago, Illinois.
For more information, please contact:
Mirada Medical
US/Worldwide: Robert Ripley
Tel: (440) 591-8638
Insource Communications
rripley(at)insourceinc(dot)com
enquiries(at)mirada-medical(dot)com
http://www.mirada-medical.com
U.S. Headquarters:
Mirada Medical USA, Inc.
999 18th Street
Suite 2025N
Denver, CO 80202
Tel: (303) 379-9228
World Headquarters:
Oxford Centre for Innovation
New Road, Oxford
OX1 1BY
United Kingdom
Tel: +44 (0) 1865 261410
About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.
The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada’s advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.
Mirada Medical was originally spun out of the University of Oxford. The company’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England.
Mirada Medical, RTx, Casemeeting, Caseaccess and XD3 are all trademarks of Mirada Medical Ltd.